HIV/HCV Treatment
HCV therapy with IFN/RBV relatively safe in patients coinfected with HIV and HCV
Published in Blood Weekly, June 10th, 2004
According to a study from the American Foundation for AIDS Research, "Human immunodeficiency virus (HIV)-infected patients increasingly experience the consequences of chronic hepatitis C virus (HCV) coinfection. This trial randomized 107 patients coinfected with HIV and HCV to receive 48 weeks of interferon alfa-2b (IFN) 3 million units three times weekly plus either a full course of ribavirin (RBV) at 800 mg/day (group A, n = 53) or 16 weeks of placebo, followed by RBV (group B; n = 54)."
"The primary endpoint of sustained viral response (SVR) rate...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
Source: Blood Weekly (2004-06-10)
More Articles from Blood Weekly
- Cell Proliferation
Hepatocyte proliferation enhanced by immobilization on 24 nm-sized gold colloid - Stem-Cell Research
Genetic profiling of hair follicle stem cells yields treatment targets - Stem-Cell Research
Stem cells derived via nuclear transplantation regenerates infarcted heart - Stem-Cell Transplantation
IFN with very low-dose PBMC infusion induces complete remission in CML relapse - Tissue Engineering
Schwann cells implanted into acellular muscle provides graft for regeneration - Acute Coronary Syndromes
Company announces reinitiation of phase IIa trial in ACS - More from this issue of Blood Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
